KEYNOTE-059 investigated pembrolizumab as third-line therapy for GC or GEJC patients, showing an overall response rate (ORR) of 22.7% for patients with CPS ≥ 1, while PD-L1-negative tumors had an ORR of 8.6%. Here, CD274 is linked to gastric cancer.